Stryker Corporation (NYSE:SYK) Given Average Rating of “Moderate Buy” by Brokerages

Stryker Corporation (NYSE:SYK) has earned an average recommendation of “Moderate Buy” from the twenty-two analysts that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $395.3333.

Several equities analysts have issued reports on SYK shares. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research report on Friday, May 1st. Truist Financial reiterated a “hold” rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Needham & Company LLC reduced their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. BTIG Research decreased their price objective on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, Robert W. Baird set a $385.00 target price on Stryker in a research report on Friday, May 1st.

Stryker Stock Performance

Shares of SYK stock opened at $313.38 on Thursday. The firm has a market capitalization of $120.14 billion, a price-to-earnings ratio of 36.27, a PEG ratio of 2.02 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $309.89 and its 200-day moving average price is $339.15. Stryker has a 12 month low of $281.00 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter last year, the business earned $2.84 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts forecast that Stryker will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 323,264 shares of company stock worth $100,659,489 over the last ninety days. 4.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Stryker

Several large investors have recently modified their holdings of SYK. Brighton Jones LLC boosted its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new stake in Stryker during the 2nd quarter worth about $205,000. Marshall Wace LLP raised its position in shares of Stryker by 107.9% in the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC acquired a new position in shares of Stryker in the 2nd quarter valued at about $219,000. Finally, HUB Investment Partners LLC acquired a new position in shares of Stryker in the 2nd quarter valued at about $253,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.